- Home
- MAG vs HCM Comparison
MAG vs HCM Comparison
Compare MAG & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAG
- HCM
- Stock Information
- Founded
- MAG N/A
- HCM 2000
- Country
- MAG Canada
- HCM Hong Kong
- Employees
- MAG N/A
- HCM N/A
- Industry
- MAG Precious Metals
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- MAG Basic Materials
- HCM Health Care
- Exchange
- MAG Nasdaq
- HCM Nasdaq
- Market Cap
- MAG 2.2B
- HCM 2.5B
- IPO Year
- MAG N/A
- HCM N/A
- Fundamental
- Price
- MAG $21.54
- HCM $17.61
- Analyst Decision
- MAG Hold
- HCM Buy
- Analyst Count
- MAG 3
- HCM 2
- Target Price
- MAG $20.50
- HCM $23.50
- AVG Volume (30 Days)
- MAG 1.3M
- HCM 56.9K
- Earning Date
- MAG 08-05-2025
- HCM 08-07-2025
- Dividend Yield
- MAG 1.86%
- HCM N/A
- EPS Growth
- MAG 57.48
- HCM N/A
- EPS
- MAG 0.88
- HCM 0.04
- Revenue
- MAG N/A
- HCM $630,201,000.00
- Revenue This Year
- MAG N/A
- HCM $14.86
- Revenue Next Year
- MAG N/A
- HCM $19.54
- P/E Ratio
- MAG $24.48
- HCM $78.60
- Revenue Growth
- MAG N/A
- HCM N/A
- 52 Week Low
- MAG $11.29
- HCM $11.51
- 52 Week High
- MAG $22.66
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- MAG 53.23
- HCM 65.30
- Support Level
- MAG $20.86
- HCM $17.36
- Resistance Level
- MAG $22.31
- HCM $18.00
- Average True Range (ATR)
- MAG 0.56
- HCM 0.33
- MACD
- MAG -0.09
- HCM 0.10
- Stochastic Oscillator
- MAG 37.78
- HCM 83.12
About MAG MAG Silver Corporation
MAG Silver Corp is a Canadian mining company. It is focused on advancing high-grade, district-scale precious metals projects in the Americas. The Company's principal asset is in the Juanicipio Mine located in Zacatecas, Mexico, which produced around 4,000 tonnes per day commercially. The company is also Interested in the Larder project. Its operations are Juanicipio, Deer Trail, and Larder. The Juanicipio Mine recognizes silver, gold, lead, and zinc revenue from concentrate sales.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.